X

Teklad Diets recertified to new ISO standard

Jul 27, 2017

Press & News

Envigo has announced that its Teklad Diets sites in Madison, WI received recertification to the new ISO9001:2015 standard. ISO 9001 is the international standard that specifies requirements for a quality management system (QMS). Organizations use the standard to demonstrate the ability to consistently provide products and services that meet customer and regulatory requirements. The ISO9001:2015 revision has re-focused on performance by combining the process approach with risk-based thinking and employing the Plan-Do-Check-Act cycle at all levels within an organization. Received in June, this certification gives Envigo’s customers’ confidence about the oversight and quality of the products they purchase for their research needs.

In mid-May, SGS North America Inc., the world’s leading inspection, verification, testing and certification company, conducted an intensive four-day audit of the Envigo Madison site. The audit revealed Envigo had established and maintained its QMS in line with requirements of the new standard. Most notable in the audit report were zero non-conformances and the evidence that Envigo management had integrated its QMS into the organization’s business processes. The site spent approximately a month prior to the audit to prepare and ensure compliance with the new standard. Companies are required to recertify to the new standard by September 2017, however Envigo chose to comply sooner to avoid any compliance delay.

Scott Schulz, Director, North American Operations commented: “At Envigo, we understand the value of our customers’ research depends on the quality of care given to research animals. We commit to producing and distributing fit-for-purpose laboratory animal diets, which help to ensure dependable and repeatable research results. The recent ISO recertification to the new standard reaffirms our commitment to enhancing the high quality of products in our Teklad portfolio which are used by thousands of biomedical and biopharmaceutical organizations worldwide.”

Avista and Envigo press release

Discover the future of inhalation technology and inhaled medications

How to select the right oncology model